Sabby Management’s Krystal Biotech KRYS Stock Holding History

Sabby Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-53,558	Closed	-$534K	–	178
2017 Q3	$534K	Buy	+53,558	New	+$540K	0.03%	97

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

TCP

Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sabby Management's KRYS Position: Q4 2017 in Review

Sabby Management sold out of Krystal Biotech (KRYS) in Q4 2017, closing a stake of 53,558 shares — an estimated $534K sold.

Sabby Management first reported a position in KRYS in Q3 2017 and held it in 1 quarter. The position peaked at $534K in Q3 2017. 13 funds tracked by Wall St. Rank hold KRYS as of Q4 2017.

Sabby Management reported no remaining Krystal Biotech position as of Q4 2017 after selling out during the quarter.
Sabby Management sold 53,558 Krystal Biotech shares in Q4 2017, an estimated $534K.
Sabby Management first reported a position in Krystal Biotech in Q3 2017 and held it in 1 quarter.
Sabby Management's Krystal Biotech position peaked at $534K in Q3 2017.
13 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2017.

Based on Sabby Management's 13F filing for Q4 2017, filed 14 Feb 2018.